Preventing invasive meningococcal disease in early infancy

References

• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196–11. doi:10.1016/S0140-6736(07)61016-2.
   PubMed Web of Science ®Google Scholar
• Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine. 2009;27(suppl2):B71–77. doi:10.1016/j.vaccine.2009.04.070.
   PubMedGoogle Scholar
• Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774–83. doi:10.1016/S1474-4422(12)70180-1.
   PubMed Web of Science ®Google Scholar
• Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–82. doi:10.1016/j.vaccine.2019.04.020.
   PubMed Web of Science ®Google Scholar
• Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, Harnden A, Mant D, Levin M. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397–403. doi:10.1016/S0140-6736(06)67932-4.
   PubMed Web of Science ®Google Scholar
• Abu Raya B, Sadarangani M. Meningococcal vaccination in pregnancy. Hum Vaccin Immunother. 2018;14(5):1188–96. doi:10.1080/21645515.2018.1445447.
   PubMed Web of Science ®Google Scholar
• Peterson ME, Li Y, Bita A, Moureau A, Nair H, Kyaw MH, Meningococcal Surveillance G, Abad R, Bailey F, Garcia IF, et al. Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health. 2019;9(1):010409. doi:10.7189/jogh.09.010409.
   PubMed Web of Science ®Google Scholar
• Parikh S, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, Safadi MA, Shao Z, Zhu B, von Gottberg A, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–98. doi:10.1016/j.jinf.2020.05.079.
   PubMed Web of Science ®Google Scholar
• Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, Christensen H, Climent Y, De Wals P, Dinleyici EC, et al. The global meningococcal initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18(1):15–30. doi:10.1080/14760584.2019.1557520.
   PubMed Web of Science ®Google Scholar
• Booy R, Gentile A, Nissen M, Whelan J, Abitbol V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother. 2019;15(2):470–80. doi:10.1080/21645515.2018.1532248.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Bennett N, Farley MM, Harrison LH, Lynfield R, Nichols M, Petit S, Reingold A, Schaffner W, Thomas A, et al. Epidemiology of infant meningococcal disease in the United States, 2006-2012. Pediatrics. 2015;135(2):e305–311. doi:10.1542/peds.2014-2035.
   PubMed Web of Science ®Google Scholar
• Judelsohn R, Marshall GS. The burden of infant meningococcal disease in the United States. J Pediatric Infect Dis Soc. 2012;1(1):64–73. doi:10.1093/jpids/pir003.
   PubMedGoogle Scholar
• Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine. 2003;21(11–12):1094–98. doi:10.1016/S0264-410X(02)00630-8.
   PubMed Web of Science ®Google Scholar
• Christensen H, Al-Janabi H, Levy P, Postma MJ, Bloom DE, Landa P, Damm O, Salisbury DM, Diez-Domingo J, Towse AK, et al. Economic evaluation of meningococcal vaccines: considerations for the future. Eur J Health Econ. 2020;21(2):297–309. doi:10.1007/s10198-019-01129-z.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2020 global summary. [accessed 2021 April 22]. http://apps.who.int/immunization_monitoring/globalsummary/schedules .
   Google Scholar
• Ku LC, Boggess KA, Cohen-Wolkowiez M. Bacterial meningitis in infants. Clin Perinatol. 2015;42(1):29–45, vii–viii. doi:10.1016/j.clp.2014.10.004.
   Web of Science ®Google Scholar
• Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, Bettinger JA. Investigators of the Canadian Immunization Monitoring Program ACTive (IMPACT). Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study. Clin Infect Dis. 2015;60(8):e27–e35. doi:10.1093/cid/civ028.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Factsheet about meningococcal disease. [accessed 2021 April 8]. https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet .
   Google Scholar
• Garges HP, Moody MA, Cotten CM, Smith PB, Tiffany KF, Lenfestey R, Li JS, Fowler VG Jr., Benjamin DK Jr. Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? Pediatrics. 2006;117(4):1094–100. doi:10.1542/peds.2005-1132.
   PubMed Web of Science ®Google Scholar
• Kiray Bas E, Bulbul A, Comert S, Uslu S, Arslan S, Nuhoglu A. Neonatal infection with Neisseria meningitidis: analysis of a 97-year period plus case study. J Clin Microbiol. 2014;52(9):3478–82. doi:10.1128/JCM.01000-14.
   PubMed Web of Science ®Google Scholar
• Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):11–17. doi:10.1186/1478-7954-11-17.
   PubMed Web of Science ®Google Scholar
• Li YA, Tsang R, Desai S, Dehhan H. Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011. Can Commun Dis Rep. 2014;40:160–69. doi:10.14745/ccdr.v40i09a01.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2018. [accessed 2021 Apr 8]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2018.pdf .
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance atlas of infectious diseases. [accessed 2021 April 8]. https://ecdc.europa.eu/en/surveillance-atlas-infectious-diseases .
   Google Scholar
• Institute of Environmental Science and Research Ltd. Notifiable diseases in New Zealand: annual report 2017. [accessed 2021 April 8]. https://surv.esr.cri.nz/PDF_surveillance/AnnualRpt/AnnualSurv/2017/2017AnnualNDReport_FINAL.pdf .
   Google Scholar
• Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, Kaczmarski EB, Mallard RH, Guiver M, Newbold LS, Borrow R. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30(24):3710–16. doi:10.1016/j.vaccine.2012.03.011.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine. 2001;19(11–12):1327–46. doi:10.1016/S0264-410X(00)00333-9.
   PubMed Web of Science ®Google Scholar
• Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, Lee BW, Lolekha S, Peltola H, Ruff TA, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008;86(2):140–46. doi:10.2471/BLT.07.040089.
   PubMed Web of Science ®Google Scholar
• Findlow H, Tapia MD, Sow SO, Haidara FC, Coulibaly F, Keita AM, Diallo F, Doumbia M, Traore A, Schluterman N, et al. Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants. Vaccine. 2019;37(18):2477–81. doi:10.1016/j.vaccine.2019.03.045.
   PubMed Web of Science ®Google Scholar
• Nunes MC, Madhi SA. Prevention of influenza-related illness in young infants by maternal vaccination during pregnancy. F1000Res. 2018;7:122. doi:10.12688/f1000research.12473.1.
   PubMedGoogle Scholar
• Bergin N, Murtagh J, Philip RK. Maternal vaccination as an essential component of life-course immunization and its contribution to preventive neonatology. Int J Environ Res Public Health. 2018;15(5):1–12. doi:10.3390/ijerph15050847.
   Web of Science ®Google Scholar
• Saso A, Kampmann B. Vaccine responses in newborns. Semin Immunopathol. 2017;39(6):627–42. doi:10.1007/s00281-017-0654-9.
   PubMed Web of Science ®Google Scholar
• Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. doi:10.1155/2012/985646.
   PubMed Web of Science ®Google Scholar
• Balmer P, Burman C, Serra L, York LJ. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118–30. doi:10.1080/21645515.2018.1454570.
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–61. doi:10.1016/S1473-3099(10)70251-6.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt. Lancet Infect Dis. 2007;7(12):797–803. doi:10.1016/S1473-3099(07)70288-8.
   PubMed Web of Science ®Google Scholar
• Vipond C, Care R, Feavers IM. History of meningococcal vaccines and their serological correlates of protection. Vaccine. 2012;30(suppl 2):B10–17. doi:10.1016/j.vaccine.2011.12.060.
   PubMed Web of Science ®Google Scholar
• Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest. 1975;56(6):1536–47. doi:10.1172/JCI108235.
   PubMed Web of Science ®Google Scholar
• World Health Organization. International travel and health: meningococcal disease. [accessed 2021 April 8]. http://www.who.int/ith/vaccines/meningococcal/en/ .
   Google Scholar
• Crum-Cianflone N, Sullivan E. Meningococcal vaccinations. Infect Dis Ther. 2016;5(2):89–112. doi:10.1007/s40121-016-0107-0.
   PubMed Web of Science ®Google Scholar
• MenAfriVac (meningococcal A conjugate vaccine). Full prescribing information. Pune (India): Serum Institute of India; 2015.
   Google Scholar
• Menjugate (Meningococcal Group C–CRM197 Conjugate Vaccine). Full prescribing information. Mississauga (ON, Canada): GlaxoSmithKline Inc; 2017.
   Google Scholar
• NeisVac-C Vaccine (Meningococcal Group C-TT Conjugate Vaccine, Adsorbed). Full Prescribing Information. Kirkland (QC, Canada): Pfizer Canada Ltd; 2015.
   Google Scholar
• Nimenrix® (meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine). Summary of Product Characteristics. Sandwich (Kent, UK): Pfizer Limited; 2019.
   Google Scholar
• Menveo® (Meningococcal (Groups A, C, Y And W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine). Full Prescribing Information. Sovicille (Italy): GlaxoSmithKline; 2018.
   Google Scholar
• Menactra® (MCV4). Full prescribing information. Sanofi Pasteur Inc: Swiftwater (PA); 2016.
   Google Scholar
• Ochoa-Azze RF. Cross-protection induced by VA-MENGOC-BC® vaccine. Hum Vaccin Immunother. 2018;14(5):1064–68. doi:10.1080/21645515.2018.1438028.
   PubMed Web of Science ®Google Scholar
• Bexsero (MenB-4C). Summary of product characteristics. Siena (Italy): GlaxoSmithKline Vaccines Srl; 2018.
   Google Scholar
• Menitorix (Haemophilus type b and meningococcal group C conjugate vaccine). Summary of product characteristics. Middlesex (UK): GlaxoSmithKline; 2016.
   Google Scholar
• McCarthy PC, Sharyan A, Sheikhi Moghaddam L. Meningococcal vaccines: current status and emerging strategies. Vaccines (Basel). 2018;6(1):12. doi:10.3390/vaccines6010012.
   PubMed Web of Science ®Google Scholar
• LaForce FM, Djingarey M, Viviani S, Preziosi MP. Lessons from the meningitis vaccine project. Viral Immunol. 2018;31(2):109–13. doi:10.1089/vim.2017.0120.
   PubMed Web of Science ®Google Scholar
• Menveo (Meningococcal Group A, C, W135 and Y conjugate vaccine). Summary of Product Characteristics. Uxbridge (Middlesex, UK): GlaxoSmithKline UK; 2015.
   Google Scholar
• Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, Mallard RH, Kaczmarski EB, Meningococcal Reference Unit. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol. 2006;55(Pt 7):887–96. doi:10.1099/jmm.0.46288-0.
   PubMed Web of Science ®Google Scholar
• Tin Tin Htar M, Jackson S, Balmer P, Serra LC, Vyse A, Slack M, Riera-Montes M, Swerdlow DL, Findlow J. Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs. BMC Public Health. 2020;20(1):1890. doi:10.1186/s12889-020-09946-1.
   PubMed Web of Science ®Google Scholar
• Ribeiro IG, Percio J, Moraes C. Evaluation of the national meningococcal disease surveillance system: Brazil, 2007-2017. Epidemiol Serv Saude. 2019;28(3):e2018335. doi:10.5123/s1679-49742019000300009.
   PubMed Web of Science ®Google Scholar
• Bijlsma MW, Brouwer MC, Spanjaard L, van de Beek D, van der Ende A. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination. Clin Infect Dis. 2014;59(9):1216–21. doi:10.1093/cid/ciu601.
   PubMed Web of Science ®Google Scholar
• Lawrence GL, Wang H, Lahra M, Booy R, McIntyre PB. Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme. Epidemiol Infect. 2016;144(11):2382–91. doi:10.1017/S0950268816000704.
   PubMed Web of Science ®Google Scholar
• Ruitenberg EJ, Houweling H. [Universal vaccination against group-C meningococci and pneumococci; summary of the advice from the Health Council of the Netherlands]. Ned Tijdschr Geneeskd. 2002;146:938–40.
   PubMedGoogle Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–43. doi:10.1086/527401.
   PubMed Web of Science ®Google Scholar
• Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L, Narbe M, Toralta J, Kodbesse B, Ngadoua C, Coldiron ME, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet. 2014;383(9911):40–47. doi:10.1016/S0140-6736(13)61612-8.
   PubMed Web of Science ®Google Scholar
• Petousis-Harris H. Impact of meningococcal group B OMV vaccines, beyond their brief. Hum Vaccin Immunother. 2018;14(5):1058–63. doi:10.1080/21645515.2017.1381810.
   PubMed Web of Science ®Google Scholar
• Holst J, Oster P, Arnold R, Tatley MV, Naess LM, Aaberge IS, Galloway Y, McNicholas A, O’Hallahan J, Rosenqvist E, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9(6):1241–53. doi:10.4161/hv.24129.
   PubMed Web of Science ®Google Scholar
• Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. Microorganisms. 2020;8(10):1521. doi:10.3390/microorganisms8101521.
   PubMed Web of Science ®Google Scholar
• Rodriguez AP, Dickinson F, Baly A, Martinez R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem Inst Oswaldo Cruz. 1999;94(4):433–40. doi:10.1590/S0074-02761999000400002.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–17. doi:10.1056/NEJMoa1901229.
   PubMed Web of Science ®Google Scholar
• Azzari C, Moriondo M, Nieddu F, Guarnieri V, Lodi L, Canessa C, Indolfi G, Giovannini M, Napoletano G, Russo F, et al. Effectiveness and impact of the 4CMenB vaccine against group B meningococcal disease in two Italian regions using different vaccination schedules: a five-year retrospective observational study (2014-2018). Vaccines (Basel). 2020;8(3). doi:10.3390/vaccines8030469
   Web of Science ®Google Scholar
• Rodrigues FMP, Marlow R, Simoes MJ, Danon L, Ladhani S, Finn A. Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal. JAMA. 2020;324(21):2187–94. doi:10.1001/jama.2020.20449.
   PubMed Web of Science ®Google Scholar
• Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–27. doi:10.1056/NEJMoa1900236.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Thomas JD, MacNeil J, Chang HY, Day M, Fisher E, Martin S, Poissant T, Schmink SE, Steward-Clark E, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak-Oregon, 2015-2016. J Infect Dis. 2017;216(9):1130–40. doi:10.1093/infdis/jix446.
   PubMed Web of Science ®Google Scholar
• Soeters HM, Whaley M, Alexander-Scott N, Kanadanian KV, MacNeil JR, Martin SW, McNamara LA, Sicard K, Vanner C, Vuong J, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college-Rhode Island, 2015-2016. Clin Infect Dis. 2017;64(8):1115–22. doi:10.1093/cid/cix091.
   PubMed Web of Science ®Google Scholar
• Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P. Impact of a mass vaccination campaign against serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019;37(31):4243–45. doi:10.1016/j.vaccine.2019.06.021.
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725. doi:10.1136/bmj.g5725.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA. [accessed 2021 March 22]. https://www.ecdc.europa.eu/sites/default/files/documents/Introduction-of-4CMenB-vaccine.pdf .
   Google Scholar
• Joint Committee on Vaccination and Immunisation. JCVI interim position statement on use of Bexsero® meningococcal B vaccine in the UK. Jul 2013 [accessed 2021 Mar 23]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/224896/JCVI_interim_statement_on_meningococcal_B_vaccination_for_web.pdf .
   Google Scholar
• Joint Committee on Vaccination and Immunisation. JCVI position statement on use of Bexsero® meningococcal B vaccine in the UK. 2014 Mar [accessed 2021 Apr 8]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/294245/JCVI_Statement_on_MenB.pdf .
   Google Scholar
• European Centre for Disease Prevention and Control. Vaccine scheduler. Vaccine schedules in all countries of the European Union. European Centre for Disease Prevention and Control (ECDC). [accessed 2020 May 18]. https://vaccine-schedule.ecdc.europa.eu/ .
   Google Scholar
• Weinberg MS. Chapter 7: family travel. Oxford University Press: CDC Yellow Book: Centers for Disease Control and Prevention; 2020.
   Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meer HC, Baker CJ, Messonnier NE, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR–2):1–28. rr6202a1 [pii].
   PubMed Web of Science ®Google Scholar
• Giuliani AR, Mattei A, Appetiti A, Pompei D, Di Donna F, Fiasca F, Fabiani L. Spontanuous demand for meningococcal B vaccination: effects on appropriateness and timing. Hum Vaccin Immunother. 2018;14(8):2075–81. doi:10.1080/21645515.2018.1466015.
   PubMed Web of Science ®Google Scholar
• Igidbashian S, Bertizzolo L, Tognetto A, Azzari C, Bonanni P, Castiglia P, Conversano M, Esposito S, Gabutti G, Icardi G, et al. Invasive meningococcal disease in Italy: from analysis of national data to an evidence-based vaccination strategy. J Prev Med Hyg. 2020;61(2):E152–E161. doi:10.15167/2421-4248/jpmh2020.61.2.1589.
   PubMedGoogle Scholar
• Presa J, Findlow J, Vojicic J, Williams S, Serra L. Epidemiologic trends, global shifts in meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review. Infect Dis Ther. 2019;8(3):307–33. doi:10.1007/s40121-019-0254-1.
   PubMed Web of Science ®Google Scholar
• Cohen R, Gaudelus J, Leboucher B, Stahl JP, Denis F, Subtil D, Pujol P, Lepetit H, Longfier L, Martinot A. Impact of mandatory vaccination extension on infant vaccine coverages: promising preliminary results. Med Mal Infect. 2019;49(1):34–37. doi:10.1016/j.medmal.2018.10.004.
   PubMed Web of Science ®Google Scholar
• Levy-Bruhl D, Desenclos JC, Quelet S, Bourdillon F. Extension of French vaccination mandates: from the recommendation of the steering committee of the citizen consultation on vaccination to the law. Euro Surveill. 2018;23:17. doi:10.2807/1560-7917.ES.2018.23.17.18-00048.
   Google Scholar
• Pace D, Gauci C, Barbara C. The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta. Eur J Clin Microbiol Infect Dis. 2020;39(10):1885–97. doi:10.1007/s10096-020-03914-8.
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F, Serra L, Safadi MAP. Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants. Expert Rev Vaccines. 2020:1–13. doi:10.1080/14760584.2020.1745070.
   PubMed Web of Science ®Google Scholar
• National Health Service. The routine immunisation schedule. [accessed 2021 May 18]. https://www.gov.uk/government/publications/the-complete-routine-immunisation-schedule .
   Google Scholar
• Masters NB, Tefera YA, Wagner AL, Boulton ML. Vaccine hesitancy among caregivers and association with childhood vaccination timeliness in Addis Ababa, Ethiopia. Hum Vaccin Immunother. 2018;14(10):2340–47. doi:10.1080/21645515.2018.1480242.
   PubMed Web of Science ®Google Scholar
• Albrecht M, Arck PC. Vertically transferred immunity in neonates: mothers, mechanisms and mediators. Front Immunol. 2020;11:555. doi:10.3389/fimmu.2020.00555.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Tetanus vaccines: WHO position paper - February 2017. Wkly Epidemiol Rec. 2017;92(6):53–76.
   PubMedGoogle Scholar
• World Health Organization. Pertussis vaccines: WHO position paper - September 2015. Wkly Epidemiol Rec. 2015;90(35):433–58.
   PubMedGoogle Scholar
• Lindley MC, Kahn KE, Bardenheier BH, D’Angelo DV, Dawood FS, Fink RV, Havers F, Skoff TH. Vital signs: burden and prevention of influenza and pertussis among pregnant women and infants - United States. MMWR Morb Mortal Wkly Rep. 2019;68(40):885–92. doi:10.15585/mmwr.mm6840e1.
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation. Advice on influenza vaccines for 2020/21. Department of Health & Social Care. [accessed 2021 April 8]. http://www.gloslmc.com/downloads/Flu/JCVI%20advice%20on%20Influenza%20vaccines%20for%202020-21.pdf .
   Google Scholar
• McCormick JB, Gusmao HH, Nakamura S, Freire JB, Veras J, Gorman G, Feeley JC, Wingo P. Antibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancy. J Clin Invest. 1980;65(5):1141–44. doi:10.1172/JCI109768.
   PubMed Web of Science ®Google Scholar
• O’Dempsey TJ, McArdle T, Ceesay SJ, Secka O, Demba E, Banya WA, Francis N, Greenwood BM. Meningococcal antibody titres in infants of women immunised with meningococcal polysaccharide vaccine during pregnancy. Arch Dis Child Fetal Neonatal Ed. 1996;74(1):F43–46. doi:10.1136/fn.74.1.F43.
   PubMed Web of Science ®Google Scholar
• Shahid NS, Steinhoff MC, Roy E, Begum T, Thompson CM, Siber GR. Placental and breast transfer of antibodies after maternal immunization with polysaccharide meningococcal vaccine: a randomized, controlled evaluation. Vaccine. 2002;20(17–18):2404–09. doi:10.1016/S0264-410X(02)00061-0.
   PubMed Web of Science ®Google Scholar
• Blanchard-Rohner G, Snape MD, Kelly DF, O’Connor D, John T, Kibwana E, Parks H, Ford K, Dull PM, Pollard AJ. Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom. Pediatr Infect Dis J. 2013;32(7):768–76. doi:10.1097/INF.0b013e318292f425.
   PubMed Web of Science ®Google Scholar
• Wak G, Williams J, Oduro A, Maure C, Zuber PL, Black S. The safety of PsA-TT in pregnancy: an assessment performed within the navrongo health and demographic surveillance site in Ghana. Clin Infect Dis. 2015;61(suppl 5):S489–492. doi:10.1093/cid/civ625.
   PubMedGoogle Scholar
• Zheteyeva Y, Moro PL, Yue X, Broder K. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the vaccine adverse event reporting system. Am J Obstet Gynecol. 2013;208(6):478e471–476. doi:10.1016/j.ajog.2013.02.027.
   Web of Science ®Google Scholar
• Myers TR, McNeil MM, Ng CS, Li R, Lewis PW, Cano MV. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2010-2015. Vaccine. 2017;35(14):1758–63. doi:10.1016/j.vaccine.2017.02.030.
   PubMed Web of Science ®Google Scholar
• Becerra-Culqui TA, Sy LS, Ackerson BK, Chen LH, Fischetti CA, Solano Z, Schmidt JE, Malvisi L, Curina C, Pellegrini M, et al. Safety of MenACWY-CRM vaccine exposure during pregnancy. Vaccine. 2020;38(12):2683–90. doi:10.1016/j.vaccine.2020.02.008.
   PubMed Web of Science ®Google Scholar